LivaNova PLC (NASDAQ:LIVN) Receives Average Recommendation of “Moderate Buy” from Analysts

LivaNova PLC (NASDAQ:LIVN) has received an average rating of “Moderate Buy” from the ten research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $74.7778.

LIVN has been the subject of several research reports. KeyCorp assumed coverage on shares of LivaNova in a research report on Friday, December 19th. They set an “overweight” rating and a $81.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of LivaNova in a research report on Friday, March 27th. Barclays increased their target price on LivaNova from $67.00 to $73.00 and gave the stock an “equal weight” rating in a research note on Friday, February 27th. Needham & Company LLC lifted their price target on LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Finally, Wall Street Zen upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th.

Institutional Investors Weigh In On LivaNova

A number of institutional investors have recently modified their holdings of the business. SG Americas Securities LLC grew its stake in shares of LivaNova by 256.6% in the first quarter. SG Americas Securities LLC now owns 86,490 shares of the company’s stock valued at $5,497,000 after acquiring an additional 62,233 shares in the last quarter. Diversified Trust Co raised its stake in LivaNova by 12.3% in the 1st quarter. Diversified Trust Co now owns 21,028 shares of the company’s stock worth $1,337,000 after purchasing an additional 2,303 shares in the last quarter. Hsbc Holdings PLC boosted its holdings in LivaNova by 260.6% in the 4th quarter. Hsbc Holdings PLC now owns 20,301 shares of the company’s stock valued at $1,255,000 after purchasing an additional 14,671 shares during the period. Corient Private Wealth LLC bought a new stake in LivaNova in the 4th quarter valued at about $302,000. Finally, Pacer Advisors Inc. grew its position in shares of LivaNova by 131.7% during the 4th quarter. Pacer Advisors Inc. now owns 16,661 shares of the company’s stock worth $1,025,000 after purchasing an additional 9,471 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

LivaNova Trading Down 0.2%

LIVN stock opened at $65.01 on Friday. LivaNova has a one year low of $34.00 and a one year high of $71.92. The stock has a market cap of $3.56 billion, a price-to-earnings ratio of -14.58 and a beta of 0.97. The company has a fifty day moving average price of $64.78 and a two-hundred day moving average price of $60.98. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.36 and a quick ratio of 1.16.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.80 by $0.06. The company had revenue of $360.92 million for the quarter, compared to analyst estimates of $354.31 million. LivaNova had a negative net margin of 17.46% and a positive return on equity of 16.54%. The company’s revenue was up 12.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.81 earnings per share. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. Equities analysts anticipate that LivaNova will post 2.85 EPS for the current year.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.